STMN2 and type 2 diabetes mellitus: We believe that the overexpression experiments suggest a mechanism whereby an increase in Stmn2 in the alpha cell inhibits glucagon secretion by targeting glucagon secretory granules for degradation in the endosome-lysosome pathway, perhaps in a manner similar to that of insulin secretory granules in Type 2 diabetes (52).